SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-007372
Filing Date
2020-02-27
Accepted
2020-02-27 16:10:40
Documents
14
Period of Report
2020-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aimt-8k_20200227.htm   iXBRL 8-K 37066
2 EX-99.1 aimt-ex991_8.htm EX-99.1 325200
3 GRAPHIC gv34h2aov4te000001.jpg GRAPHIC 8124
  Complete submission text file 0001564590-20-007372.txt   525712

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aimt-20200227.xsd EX-101.SCH 5964
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aimt-20200227_lab.xml EX-101.LAB 19671
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aimt-20200227_pre.xml EX-101.PRE 11629
7 EXTRACTED XBRL INSTANCE DOCUMENT aimt-8k_20200227_htm.xml XML 3557
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37519 | Film No.: 20662122
SIC: 2834 Pharmaceutical Preparations